{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:29:59Z","timestamp":1791250199784,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T00:00:00Z","timestamp":1615075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T00:00:00Z","timestamp":1615075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Cancer Research and Development Fund","award":["26-A-26"],"award-info":[{"award-number":["26-A-26"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12185-021-03105-x","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T12:02:22Z","timestamp":1615118542000},"page":"872-876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-2502","authenticated-orcid":false,"given":"Toshihisa","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4881-0427","authenticated-orcid":false,"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Fukushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Doke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,7]]},"reference":[{"key":"3105_CR1","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","volume":"127","author":"P Teira","year":"2016","unstructured":"Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427\u201338.","journal-title":"Blood"},{"key":"3105_CR2","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433\u201344.","journal-title":"N Engl J Med"},{"key":"3105_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40265-017-0860-8","volume":"78","author":"ES Kim","year":"2018","unstructured":"Kim ES. Letermovir: first global approval. Drugs. 2018;78:147\u201352.","journal-title":"Drugs"},{"key":"3105_CR4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1586\/14787210.2013.826989","volume":"11","author":"S Seyedmousavi","year":"2013","unstructured":"Seyedmousavi S, Mouton JW, Verweij PE, Br\u00fcggemann RJ. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther. 2013;11:931\u201341.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3105_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/jcph.1094","volume":"58","author":"WL Marshall","year":"2018","unstructured":"Marshall WL, McCrea JB, Macha S, Menzel K, Liu F, van Schanke A, et al. Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (Posaconazole or Voriconazole) in healthy subjects. J Clin Pharmacol. 2018;58:897\u2013904.","journal-title":"J Clin Pharmacol"},{"key":"3105_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.7150\/ijms.42011","volume":"17","author":"S Hikasa","year":"2020","unstructured":"Hikasa S, Shimabukuro S, Osugi Y, Ikegame K, Kaida K, Fukunaga K, et al. Tacrolimus concentration after letermovir initiation in hematopoietic stem cell transplantation recipients receiving voriconazole: a retrospective. Observational Study Int J Med Sci. 2020;17:859\u201364.","journal-title":"Observational Study Int J Med Sci"},{"key":"3105_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jac\/dkz499","volume":"75","author":"A Duong","year":"2020","unstructured":"Duong A, Sweet A, Jain R, Hill JA, Pergam SA, Boeckh M, et al. Clinically significant drug interaction: letermovir and voriconazole. J Antimicrob Chemother. 2020;75:775\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"3105_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/tri.12225","volume":"27","author":"S Stoelben","year":"2014","unstructured":"Stoelben S, Arns W, Renders L, Hummel J, M\u00fchlfeld A, Stangl M, et al. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int. 2014;27:77\u201386.","journal-title":"Transpl Int"},{"key":"3105_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00007691-199806000-00001","volume":"20","author":"M Kimura","year":"1998","unstructured":"Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit. 1998;20:243\u20137.","journal-title":"Ther Drug Monit"},{"key":"3105_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2133\/dmpk.18.48","volume":"18","author":"T Shimizu","year":"2003","unstructured":"Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, et al. Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet. 2003;18:48\u201370.","journal-title":"Drug Metab Pharmacokinet"},{"key":"3105_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/00008571-199910000-00001","volume":"9","author":"HG Xie","year":"1999","unstructured":"Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4\u2019-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999;9:539\u201349.","journal-title":"Pharmacogenetics"},{"key":"3105_CR12","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1080\/10428194.2017.1300897","volume":"58","author":"T Yasu","year":"2017","unstructured":"Yasu T, Konuma T, Kato S, Kurokawa Y, Takahashi S, Tojo A. Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients. Leuk Lymphoma. 2017;58:2731\u20133.","journal-title":"Leuk Lymphoma"},{"key":"3105_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","volume":"102","author":"B Moriyama","year":"2017","unstructured":"Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther. 2017;102:45\u201351.","journal-title":"Clin Pharmacol Ther"},{"key":"3105_CR14","doi-asserted-by":"publisher","first-page":"106078","DOI":"10.1016\/j.intimp.2019.106078","volume":"78","author":"L Cheng","year":"2020","unstructured":"Cheng L, Xiang R, Liu F, Li Y, Chen H, Yao P, et al. Therapeutic drug monitoring and safety of voriconazole in elderly patients. Int Immunopharmacol. 2020;78:106078.","journal-title":"Int Immunopharmacol"},{"key":"3105_CR15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1124\/dmd.114.061093","volume":"43","author":"RR Shah","year":"2015","unstructured":"Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Disposition: Biol Fate Chem. 2015;43:400\u201310.","journal-title":"Drug Metab Disposition: Biol Fate Chem"},{"key":"3105_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1054\/jcaf.2002.127773","volume":"8","author":"RF Frye","year":"2002","unstructured":"Frye RF, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail. 2002;8:315\u20139.","journal-title":"J Card Fail"},{"key":"3105_CR17","doi-asserted-by":"crossref","unstructured":"Hikasa S, Shimabukuro S, Osugi Y, Ikegame K, Kaida K, Fukunaga K, et al. Decrease in voriconazole concentration-to-dose ratio after letermovir initiation: a retrospective, observational study. Bone Marrow Transplant. 2020.","DOI":"10.1038\/s41409-020-01093-w"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03105-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03105-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03105-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T16:21:03Z","timestamp":1621527663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03105-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,7]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["3105"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03105-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,7]]},"assertion":[{"value":"18 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}